Antigenics Inc. (New York) Cancer Vaccine Study Shows Mixed Results

Feb 20 (Reuters) - Antigenics Inc said a late-stage trial of its cancer vaccine, Oncophage, in the treatment of metastatic melanoma, a serious form of skin cancer, did not meet its primary goal of overall survival.

MORE ON THIS TOPIC